Blog

DEEP RESEARCH · HanAll Biopharma pipeline

HanAll Biopharma: An R&D Company Levered To The FcRn Franchise

A pipeline review centered on IMVT-1402, tanfanercept, HL192, and the Roivant/Immunovant partnership

Date: 2025-07-19 · Biopharma pipeline and licensing analysis · Original Naver Blog post

Investment decisions are your own responsibility. This material is research and is not a recommendation to buy or sell.

0. Bottom line first

HanAll’s core value is tied to its anti-FcRn antibody franchise, especially the clinical and commercial success of the second-generation asset IMVT-1402 (HL161ANS). Tanfanercept and HL192 are meaningful options, but IMVT-1402 is the center of the thesis.

Official fact: The source describes HanAll as a company funding high-risk R&D with domestic pharmaceutical revenue and licensing milestones. The attached audio is available as a Gemini audio file.

Interpretation: I read HanAll less as a biotech that bears the full cost of global commercialization and more as a finder-partner model: discover promising assets, then put them into the capital and clinical engine of partners such as Roivant and Immunovant.

HanAll value architectureDomestic business + licensing + royalty option
IMVT-1402Anti-FcRn, best-in-class candidate
BatoclimabEfficacy data and development guide
TanfanerceptDry-eye phase 3 retry
HL192High-risk Parkinson’s option
The long-term inflection point is potential double-digit royalties after IMVT-1402 commercialization

1. The FcRn Franchise

The source explains autoimmune disease as a condition in which IgG antibodies attack the body’s own tissue. FcRn works like an intracellular “recycling center” that protects IgG and keeps it circulating longer. FcRn inhibitors block that recycling route and reduce pathogenic IgG.

Official fact: Batoclimab (HL161) was developed as a fully human monoclonal antibody in a subcutaneous formulation. It showed IgG reduction and symptom-improvement signals in diseases such as MG and TED, but LDL increases and albumin decreases were observed in some patients.

Official fact: The 2017 Roivant licensing deal totaled up to USD 502.5 million, including a USD 30 million upfront payment, USD 20 million in R&D support, and USD 452.5 million in potential milestones, with sales royalties separate.

Interpretation: Batoclimab is better viewed as the first-generation asset that opened the path for IMVT-1402. Its broad clinical dataset can help de-risk late-stage trial design for the successor molecule.

MECHANISM

FcRn inhibition

A targeted immune-modulation approach that prevents pathogenic IgG recycling.

GEN 1

Batoclimab

Efficacy signals were meaningful, but LDL and albumin issues limited its chronic-disease commercial profile.

GEN 2

IMVT-1402

Designed to preserve IgG reduction while minimizing effects on LDL and albumin.

2. IMVT-1402 Positioning

Official fact: In preclinical and phase 1 data, IMVT-1402 showed deep, dose-dependent IgG reduction similar to batoclimab while effects on albumin and LDL cholesterol were presented as placebo-like.

Official fact: Immunovant aimed to initiate 4 to 5 registrational trials by 2025 and expand to 10 indications by 2026. The source mentions MG, CIDP, Graves’ disease, difficult-to-treat rheumatoid arthritis, Sjögren’s disease, and cutaneous lupus erythematosus.

Interpretation: The competitive bar is high. Argenx’s Vyvgart proved demand with about USD 1.2 billion of 2023 sales and USD 2.2 billion of 2024 sales, while UCB’s Rystiggo and J&J’s nipocalimab are also in the field. IMVT-1402 has to prove superiority in efficacy, safety, and self-administered subcutaneous convenience.

Competitive axisMeaning in the sourceWhat IMVT-1402 must prove
EfficacyDeep and sustained IgG reductionConnection to clinical improvement
SafetyMinimal LDL and albumin effectsChronic-use differentiation
ConvenienceLow-volume subcutaneous self-administrationPatient-centered advantage over IV use
MarketFcRn market forecast above USD 10 billion annuallyAbility to gain share as a later entrant

3. Tanfanercept And HL192

Official fact: Tanfanercept (HL036) is an ophthalmic anti-TNF biologic targeting TNF-α in dry eye disease. VELOS-3 missed its co-primary endpoints, CCSS and EDS, but the secondary Schirmer test showed statistically significant tear-production improvement versus placebo.

Official fact: HanAll is running VELOS-4 with Schirmer test elevated to the primary endpoint. The U.S. trial is described as enrolling 750 patients, with top-line data expected in 2026. The source cites a global dry-eye market above USD 7 billion in 2023 and forecast at USD 13 billion by 2032.

Interpretation: Tanfanercept addresses a large market, but this is a high-risk retry built around converting a secondary signal into a primary endpoint. It is an option, not the core of the thesis.

Official fact: HL192 is a Parkinson’s candidate that activates Nurr1, aiming to protect dopaminergic neurons and restore function. It is being co-developed by HanAll, Daewoong Pharmaceutical, and NurrOn Pharmaceuticals. In healthy adults, phase 1 showed safety and tolerability without serious adverse events.

Interpretation: HL192 has large upside if it works, but given the difficulty of neurodegenerative disease development, I treat it as a portfolio call option.

4. Financial Model And Watch Points

Official fact: The source says HanAll funds R&D through its domestic prescription-drug business and partner milestones, and cites R&D expense at about 19% of sales on average. It also describes the balance sheet as having little debt.

Interpretation: Over the next 1 to 2 years, domestic sales and IMVT-1402 clinical/regulatory milestones matter most. Over 3 to 5 years and beyond, IMVT-1402 commercialization royalties could change the company’s value. My checklist is late-stage IMVT-1402 data, batoclimab TED phase 3 data, VELOS-4 results, and Immunovant’s execution speed.

Sources

Naver original